Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Differential laboratory passaging of SARS-CoV-2 viral stocks impacts the in vitro assessment of neutralizing antibodies

PLoS ONE(2024)10.1371/journal.pone.0289198Source: DataRank Database

Differential laboratory passaging of SARS-CoV-2 viral stocks impacts the in vitro assessment of neutralizing antibodies is a research paper published in PLoS ONE (2024). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access0 citations

Download PDF

Cite:

Linked data & code

bioproject refseq pdb

Data availability

Repositories this paper deposited data in (declared in PubMed).

BioProjectPRJNA978027

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.00)OA: goldTopics (24)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Jeffrey A. Kimbrel ORCID,Jose Manuel Martí ORCID,James B. Thissen ORCID,Edwin A. Saada ORCID,Tracy Weisenberger ORCID

Live enrichment

PubMed:38271318 PMC:PMC10810540 OpenAlex:https://openalex.org/W4391217490

U.S. Department of Energy

Grant: DE-AC52-07NA27344

Department of Energy, Office of Science

Grant: SCW1700

Department of Energy, Office of Science

Grant: LDRD 20-ERD-064

FWCI

0.00

Citation Percentile

0.0%

goldLicense: cc-by

journalhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0289198&type=printable

publisherhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0289198&type=printable

publisherhttps://dx.plos.org/10.1371/journal.pone.0289198

journalhttps://doi.org/10.1371/journal.pone.0289198

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38271318

Fields of Study

SARS-CoV-2 and COVID-19 ResearchVirus-based gene therapy researchAnimal Virus Infections Studies

MeSH Terms

COVID-19SARS-CoV-2Antibodies, ViralHumansImmune SeraNeutralization TestsAntibodies, NeutralizingSpike Glycoprotein, Coronavirus

Keywords

VirologyPolyclonal antibodiesNeutralizationBiologyAntiserumMonoclonal antibodySerial passageVirusAntibodyNeutralizing antibodyPopulationGeneticsMedicine

Sustainable Development Goals

SDG 0: Life in Land

Differential laboratory passaging of SARS-CoV-2 viral stocks impacts the in vitro assessment of neutralizing antibodies

FAIR Checklist

Authors (11)

Funding (3 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)